Table V.
Trauma time 0 | Controls | ||||||
---|---|---|---|---|---|---|---|
|
|||||||
Sample | Median (per µL) | IQR | % of total MV | Median (per µL) | IQR | % of total MV | % of trauma patients >95% CI of controls |
CD41+/AV+ | 177* | 65–456 | 17 | 86 | 65–127 | 24 | 60 |
CD235+/AV+ | 171** | 98–290 | 17† | 38 | 26–78 | 8 | 67 |
AnnV+ | 573** | 364–941 | 56 | 215 | 128–524 | 53 | 61 |
CD31+/41− | 16 | 10–35 | 2 ^ | 17 | 9–34 | 5 | 18 |
CD14+/142+ | 30 | 10–47 | 3 | 12 | 9–36 | 3 | 47 |
CD41+/142+ | 30 | 9–52 | 3 | 13 | 11–42 | 4 | 41 |
CD45+/142+ | 27 | 9–48 | 2 | 12 | 8–45 | 3 | 8 |
Key: AnnV – Annexin V; CI – confidence interval. Trauma cohort data at admission are compared with control data. There are significantly greater numbers of procoagulant MV present (AnnV+; p≤0.001) in the trauma samples which are of both platelet and red cell origin
denotes p<0.05
denotes p≤0.001
When comparing the distribution of MV subtypes, there is a greater proportion of CD235a+/AnnV+ MV
(denotes p=0.02, Mann–Whitney U) and a lower proportion of CD31+/41- MV
(denotes p=0.004, Mann–Whitney U) in the plasma of trauma patients.